AMGN Amgen Inc

Price (delayed)

$253.65

Market cap

$135.34B

P/E Ratio

20.26

Dividend/share

$7.76

EPS

$12.52

Enterprise value

$164.54B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
AMGN's EPS is up by 28% year-on-year and by 6% since the previous quarter
The net income has grown by 22% YoY and by 3.9% from the previous quarter
Amgen's equity has plunged by 56% YoY but it has soared by 51% from the previous quarter
The debt rose by 6% since the previous quarter and by 3% year-on-year

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
533.58M
Market cap
$135.34B
Enterprise value
$164.54B
Valuations
Price to earnings (P/E)
20.26
Price to book (P/B)
37.14
Price to sales (P/S)
5.15
EV/EBIT
18.17
EV/EBITDA
13.26
EV/Sales
6.25
Earnings
Revenue
$26.33B
EBIT
$9.06B
EBITDA
$12.41B
Free cash flow
$9B
Per share
EPS
$12.52
Free cash flow per share
$16.82
Book value per share
$6.83
Revenue per share
$49.21
TBVPS
$66.52
Balance sheet
Total assets
$63.7B
Total liabilities
$60.05B
Debt
$38.7B
Equity
$3.65B
Working capital
$9.73B
Liquidity
Debt to equity
10.6
Current ratio
1.68
Quick ratio
1.17
Net debt/EBITDA
2.35
Margins
EBITDA margin
47.1%
Gross margin
75.8%
Net margin
26%
Operating margin
36.6%
Efficiency
Return on assets
11.2%
Return on equity
199.7%
Return on invested capital
19%
Return on capital employed
18.3%
Return on sales
34.4%
Dividend
Dividend yield
3.06%
DPS
$7.76
Payout ratio
62%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
-0.48%
1 week
-3.64%
1 month
-3.7%
1 year
13.24%
YTD
-3.42%
QTD
-3.42%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$26.33B
Gross profit
$19.95B
Operating income
$9.64B
Net income
$6.84B
Gross margin
75.8%
Net margin
26%
AMGN's operating income is up by 31% year-on-year and by 3% since the previous quarter
The company's operating margin rose by 28% YoY and by 3.1% QoQ
The net income has grown by 22% YoY and by 3.9% from the previous quarter
The net margin rose by 19% year-on-year and by 4.4% since the previous quarter

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
20.26
P/B
37.14
P/S
5.15
EV/EBIT
18.17
EV/EBITDA
13.26
EV/Sales
6.25
AMGN's EPS is up by 28% year-on-year and by 6% since the previous quarter
The P/E is 16% below the 5-year quarterly average of 24.2 and 3.5% below the last 4 quarters average of 21.0
The stock's price to book (P/B) is 62% more than its 5-year quarterly average of 22.9 but 41% less than its last 4 quarters average of 63.2
Amgen's equity has plunged by 56% YoY but it has soared by 51% from the previous quarter
The P/S is 5% more than the last 4 quarters average of 4.9 but 2.8% less than the 5-year quarterly average of 5.3
The revenue has grown by 2.2% year-on-year

Efficiency

How efficient is Amgen business performance
The ROE has grown by 39% from the previous quarter
AMGN's return on assets is up by 24% year-on-year and by 3.7% since the previous quarter
AMGN's return on sales is up by 16% year-on-year and by 3.9% since the previous quarter
The ROIC has grown by 12% YoY

Dividends

What is AMGN's dividend history
DPS
$7.76
Dividend yield
3.06%
Payout ratio
62%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 6% more than its total liabilities
AMGN's quick ratio is up by 18% since the previous quarter
Amgen's current ratio has increased by 10% from the previous quarter and by 2.4% YoY
AMGN's debt to equity has soared by 132% YoY but it is down by 30% QoQ
Amgen's equity has plunged by 56% YoY but it has soared by 51% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.